NVSI-06-09 / Sinopharm - LARVOL DELTA

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) (clinicaltrials.gov) - P2 | N=516 | Active, not recruiting | Sponsor: National Vaccine and Serum Institute, China | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial. (PubMed, Signal Transduct Target Ther) - "Similarly, the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those by BBIBP-CorV. Our findings indicated that a booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against divergent SARS-CoV-2 variants, including Omicron and its sub-lineages."

Clinical • Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial (clinicaltrials.gov) - P3 | N=16000 | Recruiting | Sponsor: National Vaccine and Serum Institute, China | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial (clinicaltrials.gov) - P3 | N=16000 | Not yet recruiting | Sponsor: National Vaccine and Serum Institute, China

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) (clinicaltrials.gov) - P2 | N=516 | Recruiting | Sponsor: National Vaccine and Serum Institute, China | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) (clinicaltrials.gov) - P2 | N=516 | Not yet recruiting | Sponsor: National Vaccine and Serum Institute, China

New P2 trial • Infectious Disease • Novel Coronavirus Disease